A new hormonal therapy designed to treat uterine fibroids called relugolix has finished a Phase 3 study in Japan, and the results are positive. That’s welcome news for a SoftBank-based company based in Basel, Switzerland called Roivant Sciences that’s separately dealing with much lousier news. But let’s back up a bit first. The Phase 3 trial was one of several Phase 3 trials… Read Morevia Zero Tech Blog